LENZ vs NTLA: fair value comparison
LENZ Therapeutics, Inc. and Intellia Therapeutics, Inc. · Updated 2026-10-19
LENZ has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NTLA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, LENZ currently ranks higher by quality score.
| LENZ | NTLA | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $3.27 | $11.42 |
| 12-month range | $3.27–$31.97 | $8.04–$25.89 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #190 of 301 Healthcare | #191 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| Revenue growth | — | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: LENZ fair value analysis · NTLA fair value analysis